Technical Analysis for MGTX - MeiraGTx Holdings plc

Grade Last Price % Change Price Change
grade C 10.95 -9.43% -1.14
MGTX closed down 9.43 percent on Monday, December 17, 2018, on 1.89 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical MGTX trend table...

Date Alert Name Type % Chg
Dec 17 Stochastic Reached Oversold Weakness 0.00%
Dec 17 Below Lower BB Weakness 0.00%
Dec 17 Down 3 Days in a Row Weakness 0.00%
Dec 17 Lower Bollinger Band Touch Weakness 0.00%
Dec 17 Oversold Stochastic Weakness 0.00%
Dec 14 NR7 Range Contraction -9.43%
Dec 14 Inside Day Range Contraction -9.43%
Dec 13 20 DMA Resistance Bearish -10.17%
Dec 13 50 DMA Resistance Bearish -10.17%
Dec 13 Lower Bollinger Band Touch Weakness -10.17%

Older signals for MGTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
  • Earnings date: 2018-11-14
MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.
Is MGTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 12 MeiraGTx Announces Publication of New Research Identifying Underlying Mechanism of Functional Improvement Seen with AAV-GAD Gene Therapy in Parkinson’s Disease
Dec 10 Homology Medicines up 4%
Nov 8 MeiraGTx beats by $0.04
Nov 8 MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 31 MeiraGTx nabs rights to gene therapy for dry eye & dry mouth disorder
Oct 31 MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia
Oct 25 MeiraGTx Expands Leadership Team with Appointment of Katherine Breedis as Chief Financial Officer
Oct 16 MeiraGTx inks gene therapy research agreement with Johnson & Johnson
Oct 16 MeiraGTx Enters Collaboration with Johnson & Johnson Innovation to Develop Regulatable Gene Therapy Treatment using MeiraGTx Riboswitch Technology
Oct 9 MeiraGTx acquires Vector Neurosciences in all-stock deal
See more MGTX news...
Indicators
Indicator Value
52 Week High 15.49
52 Week Low 7.98
Average Volume 34,506
200-Day Moving Average 0.0
50-Day Moving Average 13.0714
20-Day Moving Average 12.8525
10-Day Moving Average 12.627
Average True Range 1.0191
ADX 39.05
+DI 7.9239
-DI 28.2856
Chandelier Exit (Long, 3 ATRs ) 11.1927
Chandelier Exit (Short, 3 ATRs ) 13.8573
Upper Bollinger Band 14.187
Lower Bollinger Band 11.518
Percent B (%b) -0.21
BandWidth 20.766388
MACD Line -0.3027
MACD Signal Line -0.1014
MACD Histogram -0.2013
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.94
Resistance 3 (R3) 13.11 12.62 12.61
Resistance 2 (R2) 12.62 12.11 12.53 12.50
Resistance 1 (R1) 11.78 11.80 11.54 11.61 12.39
Pivot Point 11.29 11.29 11.17 11.21 11.29
Support 1 (S1) 10.46 10.79 10.21 10.29 9.51
Support 2 (S2) 9.97 10.47 9.88 9.40
Support 3 (S3) 9.13 9.97 9.29
Support 4 (S4) 8.96